Although members of the RAS protein family (Ha-, Ki-, and N-RAS) are known to play a key role in normal cell proliferation and to be frequently mutated in naturally occurring tumors, it remains unclear which of these proteins functions to regulate growth in normal cells. 
The Ras family consists of three highly homologous proteins, each of which can function to transduce physiological signals. It has become clear that Ras proteins are members of an extended family of GTPases, including proteins involved in protein synthesis and signal transduction. They function as binary switches, cycling between the active GTP-bound form and the inactive GDP-bound form (1, 2) . The activity of Ras proteins is regulated positively by nucleotide exchange factors and negatively by the GTPase activating protein and by neurofibromin. The GTP binding functions and interactions with regulatory proteins and potential downstream effector molecules are primarily localized within the amino-terminal half of the protein.
In this region there are few amino acid differences between the three members of this family: Kirsten (Ki-Ras), Harvey (HaRas) and neural (N-Ras). This fact, along with the observation that naturally occurring oncogenic mutations in each have been identified, suggests that they might function identically. On the other hand, they differ widely in the carboxyl terminus, a region required for lipid modification and membrane attachment and thereby for biological function (3) . Although there is some tissue-specific distribution of the three family members, most tissues express multiple forms. However, in many tissues, oncogenic mutations identified in tumors tend to be localized in one or another member of this gene family. Consequently, it is critical to assess the biological importance of individual family members within a given cell or tissue type.
Ras proteins play central roles in the control of normal and transformed cell growth, as well as other important biological processes (4 -6) . The evidence supporting this conclusion comes from: 1) the fact that oncogenic ras mutations have been found in a variety of animal tumors as well as 10 -25% of all human malignancies (7-9); 2) the alteration of growth properties of a variety of cell lines following expression of oncogenic ras mutants or the high level expression of normal Ras proteins (for example, microinjection of Ha-Ras protein into serum-starved NIH/3T3 fibroblasts can both stimulate DNA synthesis and induce morphological transformation without requirement for mitogens (10) ); and 3) the inhibition of cellular proliferation following neutralization of cellular Ras activity. This has been achieved by disruption of the activated Ki-ras gene by homologous recombination (11) , inhibition of oncogenic Ha-ras (12) and Ki-ras mRNA (13) by antisense oligos, 1 or interference with posttranslational modifications of Ras proteins by farnesyltransferase inhibitors (14) . In normal diploid cells, the involvement of Ras proteins in proliferation was originally demonstrated by microinjection of a neutralizing anti-Ras antibody (15, 16) . This observation has recently been further strengthened by studies using dominant inhibitory ras mutants (17) (18) (19) . The question, however, still remains which Ras protein(s) are required for normal diploid cell proliferation.
Ras proteins function in the control of proliferation by playing a critical role in the proliferative signaling pathway, which is initiated by peptide growth factors and which leads to the activation of raf and MAP kinases. It is becoming increasingly clear, however, that Ras activity also affects a number of other signaling pathways. Although raf proteins are clearly effectors of Ras action, it is possible that other molecules also function as Ras effectors (20) . These molecules might be involved in other functions of Ras, such as its involvement in the control of cellular migration (21) , differentiation, and cytoskeletal rear-rangements. It is possible that different members of the Ras family might be involved in separate downstream signaling processes; alternatively, each of the proteins might function similarly and together constitute a functional redundancy within this critical signaling pathway.
Because of its central role in the control of proliferation, together with the frequency with which it is mutated in naturally occurring tumors, a number of approaches have been designed to inhibit the function of Ras in an effort to control cellular growth. Antisense oligonucleotides have many attractive features in this application because they have the potential to inhibit separate members of the Ras family or mutant versus cellular ras genes (22, 23) . Antisense oligonucleotides can be complementary to pre-mRNA or mRNA molecules leading to the destruction of target mRNA, presumably by directing endonuclease (RNase H) to the target mRNA (24) . The subsequent elimination of the protein product of the mRNA, however, requires that the preexisting protein within the cell be degraded by normal means. This presents a particularly difficult challenge in the study of Ras because Ras proteins have half-lives in the range of 24 h (3). Nevertheless, several groups have recently reported that oligonucleotides directed against oncogenic ras genes can substantially inhibit Ras-dependent tumor cell growth in vitro and in vivo (12, 25, 26) . To our knowledge, however, no studies have been described using antisense oligonucleotides to evaluate the function of individual Ras proteins in normal cell proliferation. In this study, we evaluated several oligonucleotides (against Ha-or Ki-RAS) synthesized using a chemistry designed to promote maximal stability and effectiveness within the cell and have used these compounds to study the role of different RAS genes in the growth of normal and tumor cells.
MATERIALS AND METHODS
Materials-Phosphorothioate oligodeoxynucleotides (oligos) were synthesized using an Applied Biosystems 380B automated DNA as detailed previously (23, 27) . Oligonucleotide ISIS 2570 is a 17-mer targeted to the codon 12 mutation (GUG) of Ha-RAS of EJ bladder carcinoma cells (CCA-CAC-CGA-CGG-CGC-CC) (27) ; ISIS 2503 is a 20-mer targeted to the initiation codon (AUG) of c-Ha-RAS mRNA (TCC-GTC-ATC-GCT-CCT-CAG-GG) (23) ; and ISIS 6957 is a 20-mer targeted to the 5Ј-UTR of Ki-RAS (CAG-TGC-CTG-CGC-CGC-GCT-CG) (28) . ISIS 1966 is a 17-mer targeted to human immunodeficiency virus and served as a control oligo for the studies in T24 cells (GAG-CTC-CCA-GGC-TCA-GA), whereas 1082 is a 21-mer targeted to herpes simplex virus and was used as a control for the study in MRC-5 and J-82 cells (GCG-GAG-GTC-CAT-GTC-GTA-CGC) (29) . All these oligos are phosphorothioate oligodeoxynucleotides and were purified as described previously (23) . Because intracellular degradation (catabolism) of oligos varies as a function of length under certain situations (24) , oligonucleotides of the same or similar length were used as controls.
Human bladder carcinoma T24 (Ha-ras mutation) and J-82 cells, as well as human normal lung fibroblasts (MRC-5), were obtained from American Type Culture Collection and used in this laboratory as reported previously (16) . Dulbecco's modified Eagle's medium and fetal bovine serum were purchased from Celox Laboratories, Inc. (Hopkins, MN) and BioWhittaker (Walkersville, MA), respectively. Lipofectin and other cell culture materials were provided by Life Technologies, Inc. (Grand Island, NY). Anti-Ras monoclonal antibody Y13-259 was prepared from ascites of a nude mouse bearing the rat hybridoma without further purification as described previously (30, 31) . Goat anti-rat IgG peroxidase and rabbit IgG fraction to rat IgG were purchased from Boehringer Mannheim and Organon Teknika Corporation (Durham, NC), respectively. Protein A-Sepharose 4B was from Zymed (South San Francisco, CA). The reagents and films for ECL were provided by DuPont. ␥-32p-ATP and other standard reagents for Northern blot were purchased from ICN Biochemicals (Irvine, CA) and Boehringer Mannheim. Plasmid RA-15 containing the Ha-ras insert and plasmid 41027 containing the Ki-ras insert were obtained from American Type Culture Collection and used as probes for Northern blot analysis. All other chemicals were purchased from Sigma.
Antiproliferation Experiment-Cells used for this study were maintained in monolayer culture in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, nonessential amino acids, sodium pyruvate, and antibiotics at 37°C, 5% CO 2 . Cells were seeded at 1 ϫ 10 5 /ml on 6-well plates (2 ml/well) and 24 h later were washed with prewarmed phosphate-buffered saline and treated with oligonucleotides in Lipofectin containing Opti-MEMI medium with a fixed ratio of oligo versus Lipofectin (2.5 l of Lipofectin per 100 nM oligo) for 4 h. Thereafter, the oligo-containing medium was replaced with normal Dulbecco's modified Eagle's medium, and cell number was counted with a hemocytometer at different times following the treatments. For T24 cells, autoradiography was also performed to verify cell counting data. This was done by adding 5 Ci [
3 H]thymidine to each well at 24 and 48 h after the treatment; the [ 3 H]thymidine remained in culture for additional 24 h before washing and fixation. The rest of the procedure for autoradiography has been described previously (16) . The results of these antiproliferation studies were analyzed with Student's t test for the statistically significant difference.
Immunoprecipitation and Western Blot Analysis-Cells were plated and treated the same as in the antiproliferation assay. 48 h after the oligo treatment, cells were lysed in ice-cold lysis buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% bovine serum albumin) containing 1 mM phenylmethylsulfonyl fluoride, 20 g/ml aprotinin, and 20 g/ml leupeptin (32) . Protein content in the lysates was determined using Bio-Rad/CD kit. For immunoprecipitation, cell lysate containing 400 g of protein was immunoprecipitated by adding 4 l of rat anti-Ras antibody Y13-259 and incubating for 1 h at 4°C. As a control, 4 g of rat IgG was also added to the untreated cell lysate containing the same amount of protein and treated as above. Protein A-Sepharose was washed four times in the lysis buffer and precoated with rabbit anti-rat IgG by adding 0.3 ml of the antibody solution (1 mg/ml), followed by incubation for 1 h at 4°C with constant mixing. 50 l of this protein A-Sepharose-anti-rat IgG mixture slurry was then added to each sample and incubated at 4°C for another 1 h. Following washing (three times), the immune complex containing RAS p21 and anti-Ras antibody was denatured with an equal volume of 2 ϫ Laemmli loading buffer and heated for 5 min at 100°C. The resulting sample was subjected to 12.5% polyacrylamide gel electrophoresis (33) . The protein was then transferred to a nitrocellulose membrane using a semidry transfer apparatus (Bio-Rad). Immunodetection of p21 RAS protein was achieved by overnight incubation of the membrane with the anti-Ras antibody ascites at 4°C (1 ϫ 1000 dilution), followed by incubation with anti-rat IgG peroxidase conjugate (1 ϫ 1000) and visualized by chemiluminescence. At least two independent immunoprecipitations were performed for each cell line, and one representative is shown here. Ha-Ras protein CR6116 was used as a positive control for every immunodetection.
Northern Blot Analysis-24 h after oligo treatment, mRNA was prepared from cells (T24, MRC-5, J-82) using guanidinium isothiocyanate. mRNA was isolated by centrifugation of the cell lysates over a cesium chloride step gradient (34) . Northern analysis was performed as described previously (35) . The plasmid RA-15 containing the Ha-RAS insert and plasmid 41027, which contains the Ki-RAS cDNA, were obtained from American Type Culture Collection. The same blot was also probed with a G3PDH probe as a control for equal loading.
RESULTS

Growth Inhibitory Effects of Anti-RAS Oligonucleotides in T24 Cells
-Antisense oligonucleotides were first tested in T24 cells, which are known to contain a mutation at codon 12 in the c-Ha-RAS gene (36) . Previous anti-Ras antibody microinjection studies demonstrated that these cells require, to a large extent, the activity of at least one member of the Ras family for proliferation (5, 16). Oligo treatment was for 4 h, after which the proliferation of T24 cells was monitored for several days. Proliferation was substantially inhibited by the oncogenic Ha-RAS oligo (ISIS 2570; 17 nucleotides in length, complementary to the mRNA region containing the oncogenic mutation). This inhibition was concentration-and time-dependent, with little inhibition seen at 24 h after the treatment (Fig. 1) , and a maximum inhibition of 70% seen at 72 h (see Figs. 1 and 4) . On the other hand, an oligonucleotide against c-Ki-RAS (ISIS 6957) was much less inhibitory, resulting in only about 26% growth inhibition with 400 nM at 72 h after the treatment (see Figs. 1 and 4 ). This level of inhibition was likely due to nonspecific effects of the oligonucleotides because this Ki-RAS oligo-induced growth inhibition was not time-or dose-dependent (Fig. 1) . The length of time required to observe growth inhibition with the oncogenic Ha-RAS oligo was most likely due to a combination of the stability of Ras proteins within the cell (half-life near 24 h) and the fact that Ras is required primarily for passage through G 1 phase (15) . Consequently, a certain time is required for the depletion of Ras proteins and to allow all cells in the culture to enter G 1 phase before inhibition of DNA synthesis can be observed.
The selective growth inhibition of T24 cells by the oncogenic Ha-RAS but not by the c-Ki-RAS oligo was further confirmed by autoradiographic evaluation (Fig. 2) . For this study, radiolabeled thymidine was added to the culture for 24 h, beginning either 24 or 48 h after the oligo treatment. Consistent with the time course observed above, this labeling assay showed that cell cycle progression was inhibited in a time-dependent manner following treatment with 400 nM of oncogenic Ha-RAS oligo (ISIS 2570; Fig. 2 ), whereas inhibition of thymidine labeling by 200 nM of the oligo was observed only at 24 h (Fig. 2, upper  panel) . This result indicates that the first 24 h after the oligo addition is critical for the anti-RAS effect and that the growth inhibition induced by this antisense oncogenic RAS oligo was apparently reversible at the lower concentration (200 nM). No consistent inhibition of labeling was observed following treatment with the c-Ki-RAS oligo. Although the dose and time dependence of inhibition of thymidine labeling only by the Ha-RAS oligo was consistently observed in this type of experiment, autoradiographic analyses are limited by the numbers of cells counted. These results, therefore, are only suggestive and are taken as a confirmation of the more reliable analyses of cell numbers described above. Together, these results suggest that oncogenic Ha-RAS protein plays a more significant role than c-Ki-RAS in T24 cell proliferation.
Growth Inhibition by c-Ki-RAS Oligo in Diploid Fibroblasts-c-Ki-and c-Ha-RAS oligos were next used to study the proliferation of diploid human lung fibroblasts (MRC-5 cells). In this experiment, oligo ISIS 1082 of 21 nucleotides (which is complementary to an unrelated sequence) was used as a control for the 20-nucleotide c-Ki-RAS oligo (ISIS 6957) and the 20 nucleotide c-Ha-RAS oligo (ISIS 2503). At 72 h after treatment, there was no substantial difference in cell number between cultures treated with c-Ha-RAS and control oligos over a concentration range from 50 to 400 nM (Figs. 3 and 4) . However, the c-Ki-RAS oligo showed a dose-dependent growth inhibition, reaching a maximum of 47% compared with the control oligo at 400 nM. There appeared to be no consistent additive effect when the c-Ki-RAS and the c-Ha-RAS oligos were combined and used to treat the MRC5 cells compared to that seen with the c-Ki-RAS oligo alone. It should be noted that the growth inhibition by c-Ki-RAS oligo in MRC-5 cells was not as great as that observed in T24 cells with the oncogenic Ha-RAS oligo (Fig. 4) . Previous antibody microinjection studies indicate that both the T24 and MRC5 cells require cellular RAS proteins for efficient proliferation (15, 16) . Our results here provide evidence that it is c-Ki-RAS that plays a dominant role in the proliferation of normal MRC-5 cells, whereas T24 cells require Ha-RAS protein for their growth.
Oligonucleotide Treatment of a RAS-independent Tumor Cell Line-To evaluate the possible involvement of RAS proteins in the proliferation of a human tumor cell line that does not contain a mutation in a RAS gene, the human bladder carcinoma cell line J-82 was examined. This line is of interest because previous experiments indicated that neither the neutralizing anti-RAS antibody nor a dominant inhibitory RAS protein was able to reduce proliferation following microinjection into these cells; therefore, this cell line can be considered a negative control for RAS-mediated growth regulation (16, 19, 37) . J-82 cells treated with 50 nM of either the c-Ki-RAS or the c-Ha-RAS oligo showed a slight growth inhibition (about 25%), which was most likely due to nonspecific effects of the oligos because this level of inhibition did not increase with either oligo even at concentrations up to 400 nM (Fig. 4) . Like MRC-5 cells, combinations of two oligos failed to show any additive growth inhibitory effect (data not shown). Thus, as expected, these results demonstrated that there was no significant growth inhibitory effect of the c-Ha-and/or c-Ki-RAS oligos in these cells. scribed above are due to actual reductions in the amounts of RAS protein, cells were treated with oligonucleotides exactly as in the proliferation assays described above. At 48 h after these treatments, lysates were prepared from treated cultures, and the RAS protein present within these lysates was immunoprecipitated with anti-RAS antibody Y13-259, an antibody that recognizes a RAS-specific sequence that is present in all cellular RAS proteins (30). The immunoprecipitated proteins were then displayed in a polyacrylamide gel, transferred to nitrocellulose membranes, and blotted with Y13-259. A strong band of RAS protein (which migrates slightly faster than the immunoglobulin light chain) was observed in each cell line tested (Fig.  5) . In T24 cells, the levels of total RAS protein were suppressed only following treatments with the oncogenic Ha-RAS oligo (Fig. 5, HЈ) . Inhibition with 200 nM oligo was barely detectable in duplicate determinations, whereas treatment with 400 nM oncogenic Ha-RAS oligo reduced the amount of total RAS protein detected in T24 cells dramatically. This result indicates that the growth inhibitory effect of the oncogenic Ha-RAS oligo in T24 cells is mediated by the decrease of the total RAS protein.
Reduction of RAS Proteins by Antisense Oligonucleotide
In MRC-5 cells, on the other hand, total RAS protein was decreased in a dose-dependent manner only after treatment with c-Ki-RAS oligo 6957 (Fig. 5, lane K) . c-Ha-RAS oligo was found to result in no significant changes of p21 RAS proteins within these cells, consistent with the effects on proliferation reported above. Because 4-h treatments with these oligos in the presence of Lipofectin can dramatically reduce the levels of RAS proteins 48 h later and produce a corresponding reduction in cellular proliferation, these oligos are apparently quite stable within the cell. Because anti-Ras antibody 259 can recognize all three isoforms of Ras protein (Ha-, Ki-, and N-Ras), the substantial depletion of p21 protein as detected with this antibody in T24 cells following the oncogenic Ha-RAS oligo and in MRC-5 cells following the c-Ki-RAS oligo treatment would indicate that in T24 cells the predominant RAS species is the oncogenic Ha-RAS protein, whereas in MRC-5 cells it is the c-Ki-RAS protein. Consequently, within these two cells types, the RAS family member that is predominantly responsible for proliferation is likely the one that is expressed at the highest level.
In J-82 cells, on the other hand, no substantial reductions in the levels of RAS proteins were observed following treatments with any of the anti-RAS oligos (Fig. 5 ). These observations apparently explain why there was no growth inhibition in these cells following the oligo treatments described above. It is not clear why RAS protein levels failed to be reduced in these cells following oligo treatments. It is possible that the N-RAS protein, which will not be affected by these oligos, is predominantly responsible for proliferation in these cells. Alternatively, possible increased stability of RAS protein in these cells could also be responsible.
Inhibition of the Target mRNAs by Oligonucleotide Treatment-Some of the oligonucleotides used in this study have been shown to inhibit production of target RAS mRNA transcripts (23, 27) . To determine the selective elimination of RAS mRNAs in these cells and to better understand the growth inhibitions described above, Northern blot analyses was performed. At 24 h after treatment with the c-Ha-RAS oligo, Ha-RAS mRNA was selectively and efficiently reduced in all three cell lines, with a greater reduction seen following treatment with 300 nM than with 100 nM oligo. There was no significant change in the level of Ha-RAS mRNA following treatments with either the control or the c-Ki-RAS oligo in any cell type tested. Treatment with oncogenic RAS oligo was fully effective in eliminating only Ha-RAS RNA in T24 cells; there was little reduction seen in MRC-5 cells and essentially none in J-82 cells (Fig. 6 ). This result confirms the selectivity of the oncogenic Ha-RAS oligo in eliminating mutated mRNA compared to c-Ha-RAS mRNA because only wild-type Ha-RAS mRNA is present in the MRC-5 and J-82 cells and there was little reduction of this message.
Two predominant Ki-RAS transcripts were found in T24 and J-82 cells, but only one in MRC-5 cells. Each of the c-Ki-RAS mRNA species was reduced following treatment with the the Ki-RAS oligo. Efficient inhibition was seen even with 100 nM treatments. On the other hand, neither the control, the oncogenic Ha-RAS, nor the c-Ha-RAS oligo treatment had any affect upon c-Ki-RAS mRNA in any of the cell lines studied (Fig. 6) . These results confirm that the oligos selectively eliminate RAS activity from the cells as indicated by reduction in proliferation, cellular RAS protein, and RAS mRNA. They should therefore be powerful tools in studying the role of individual Ras species in controlling proliferation in various cell types.
DISCUSSION
The requirement for endogenous Ras proteins in normal diploid cell proliferation was first demonstrated experimentally following microinjection of anti-Ras antibodies (5, 15, 16) . In quiescent cells stimulated with serum or in asynchronously growing cells, the injected antibody efficiently blocked entry into S phase in a number of nontransformed cell types. Because this antibody neutralizes all three isoforms of Ras protein, the microinjection studies failed to reveal which Ras isoform was responsible for promoting proliferative signaling within the cells. Similar conclusions have also been obtained with the use of dominant inhibitory mutants of ras (17) (18) (19) 37) . The present study using the gene-specific oligonucleotides provides the first experimental evidence that c-Ki-RAS protein but not c-Ha-RAS plays a dominant role in regulation of proliferation of normal diploid MRC-5 cells.
In mRNA analysis, three RAS genes have been found to be expressed in all of the tissues of mice, albeit to different levels (38) . Accordingly, histochemical examination with a Ras antibody that can discriminate the products of all three ras genes showed that Ras protein can be found in cultured cells and various normal as well as malignant tissues (39 -42) . In our present studies, one dominant Ha-RAS transcript was found in all three cell lines, whereas two Ki-RAS transcripts were detected in T24 and J-82 cells but only one in MRC-5 cells. Interestingly, two alternative spliced transcripts have been reported for human Ki-RAS (7). It is not clear whether these alternative Ki-RAS mRNA structures represent differences between human lung (MRC-5) and human bladder tissues (T-24 and J-82), differences between normal and tumor tissues, or only characteristics of the MRC-5 cell line. Whatever the explanation for different mRNA species, these results clearly demonstrate the presence of both Ki-RAS and Ha-RAS transcripts in all three cell lines and the effectiveness of these oligos for reducing the corresponding mRNA.
Because three ras genes have been found to be present in all tissues (3, 38) and because activation of either Ha-, Ki-, or N-ras has been well documented to be involved in oncogenic transformation in a variety of experimental as well as human malignancies, the possibility exists that one of three Ras proteins may be enough to maintain normal cell proliferation, with the dominant isoform varying from one tissue to another. The involvement of Ki-RAS protein in the proliferation of normal diploid fibroblasts (MRC-5 cells) as demonstrated with isoformspecific antisense oligos supports this notion. This is also apparently the case for ras-mutated tumor cells, because only one isoform of the ras gene family tends to be mutated in a single tumor type (8) , and the proliferation of these tumor cells can be inhibited by target-specific anti-RAS oligos as shown here ( Figs. 1 and 2 ) and by others (12, 25) . Not only was the proliferation of these cells specifically inhibited by individual isotype oligos, but the same oligos that inhibited cell growth were shown to efficiently reduce total RAS protein, despite the fact that the oligos were shown to be highly isotype-specific at the mRNA level. It therefore appears that a single RAS isotype is primarily involved in the control of cellular proliferation in these two cell types and that this isotype actually represents the bulk of the total RAS protein present within the cell. These results also suggest that relative RAS mRNA abundance does not correlate well with RAS protein abundance for different Ras isotypes. The final proof, however, awaits further experimentation in different tissues and cell lines using RAS isoformspecific antibodies.
Results with J-82 cells cannot at present be fully explained. These cells are known to proliferate even following neutralization of cellular RAS activity with injected anti-RAS antibody or dominant inhibitory RAS mutants (5, 19, 37) . No inhibition of proliferation was observed in these studies following oligo treatments; however, there was no apparent reduction in the amount of RAS protein, despite the efficient reduction of Haand Ki-RAS mRNAs. It is possible that either the RAS protein in these cells is N-RAS or the protein is long lived and therefore not as easily reduced following a single treatment with antisense oligo as the other cell types analyzed.
These results might have important practical implications. If similar results can be obtained in living animals, it is possible that normal cells, tumor cells, and ras-mutated tumor cells can be specifically targeted by Ras isotype-specific therapy in vivo. Thus, it might be possible to inhibit proliferation of one type of tissue without affecting others. If the proliferation of bone marrow stem cells and other rapidly proliferating tissues is also Ki-Ras-dependent, as in the case of MRC-5 cells, then their proliferation can be selectively inhibited by the Ki-RAS oligo without affecting the growth of a tumor containing a mutant Ha-ras gene. Similarly, the treatment of Ha-ras-mutated tu-mors with the Ha-ras oligonucleotides would be expected to exert specific antitumor effects without major toxicity to normal tissues.
The importance of these considerations is emphasized by previous observations made in this laboratory (16) . In that study, which involved a variety of normal and tumor cell lines, it was found that anti-Ras antibody inhibited thymidine labeling in all four normal diploid cell lines tested (including MRC-5 cells), as well as in all four tumor lines with mutant ras. On the other hand, only 3 of 10 tumor cell lines without ras activation were inhibited in proliferation by the antibody to a significant extent (16) . The use of isotype-specific oligos might now allow an expansion of these observations to determine which Ras protein(s) are required for the proliferation of individual cell FIG. 6 . Down-regulation of RAS mRNA by treatment with individual antisense oligos. Cells were treated with the indicated oligos at the concentrations listed for 4 h. After culture in normal medium for an additional 20 h, mRNA was extracted and the amounts of individual RAS mRNAs were determined. For the Northern analysis, individual filters were hybridized with probes able to selectively recognize either Ha-RAS or Ki-RAS mRNAs. After this analysis the filters were stripped and hybridized with a probe to test for equal RNA loading (glycerol-3-phosphate dehydrogenase (G3PDH)).
types. This information then can be correlated with the mutational status of ras in tumor cell lines and with the proportion of activating mutations in individual ras family members found in tumors arising from a given cell type. Perhaps the likelihood of a tumor mutation occurring in an individual ras isotype can be related to the relative abundance of expression of that isotype in the normal tissue of origin. This would explain why in the majority of tumor tissues only one ras isotype mutation can be detected (8) .
